Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron and P50 Sensory Gating in Schizophrenia
NCT00149734Phase 3Completed
- Sponsor
- University of Colorado Denver
- Start
- Jan 2005
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ondansetron in schizophrenia (2 arms), sponsored by University of Colorado Denver. Primary endpoints: P50 Sensory Gating at 3 hours and Cognitive Testing at 6 months. Started Jan 2005; status: completed.
02
Drugs
ondansetron
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00149734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00149734.